Risultati per: Efficacia e sicurezza dei farmaci GLP-1 per il diabete di tipo 2 e l’obesità

Comunicato del 13/03/2025 n°10

Un anno fa la norma per dispensarne alcuni dall’ospedale alle farmacie

Comunicato del 12/03/2025 n°9

Obbliga le aziende a contribuire a costi di trattamento delle acque

Invia notifiche tramite app in caso di dosi dimenticate

A systematic review of randomized clinical trials involving about 15 500 participants without diabetes found that all 12 of the identified glucagon-like peptide-1 (GLP-1) receptor agonists led to decreased body mass, waist circumference, and blood pressure. Of the 3 commercially available agents—liraglutide, semaglutide, and tirzepatide—the latter resulted in the greatest weight loss, with participants reporting up to an 18% change in body weight after nearly 17 months.

Molecola lonafarnib indicata contro rischio morte per progeria

Con il World Obesity Day parte un’area di approfondimenti

The US Food and Drug Administration (FDA) recently approved liraglutide to treat type 2 diabetes in combination with diet and exercise, which makes it the first generic version of Victoza and the second glucagon-like peptide-1 (GLP-1) receptor agonist authorized as a generic drug.

Regione al 6° posto tra le regioni più virtuose

To the Editor The Viewpoint by Manne-Goehler et al on developing a sustainable pathway for obesity care with glucagon-like peptide-1 receptor agonists (GLP-1RAs) is timely and addresses a critical issue for the future of effective obesity management. This article highlights the urgent need to explore not only the coverage and optimal treatment duration for GLP-1RAs but also strategies for off-ramping, defined as “the tapering or withdrawal of a GLP-1RA after [the optimal] treatment period and its replacement by an alternative approach to weight maintenance.” The authors propose a research agenda focused on studying safe off-ramping strategies, including approaches that integrate a Food is Medicine approach, define the optimal duration of GLP-1RA therapy before off-ramping, explore broader health and metabolic implications of off-ramping, and identify factors that predict successful transitions and long-term maintenance of outcomes for patients.

Cinque abitudini per mangiare sano e rispettare ritmo circadiano

VII Rapporto Farmacia, forti disparità regionali e generazionali

This Medical News article discusses safety concerns around compounded semaglutide and tirzepatide, including how clinicians can help prevent dosing errors.

Bilancio della 25/a edizione delle Giornate di raccolta del Banco Farmaceutico